Seeking Alpha

Navidea Biopharmaceuticals (NAVB +0.8%) bucks a weak tape after saying it's commenced enrollment...

Navidea Biopharmaceuticals (NAVB +0.8%) bucks a weak tape after saying it's commenced enrollment in Phase 2b positron emission tomography imaging studies of NAV4694, a scan for detecting cerebral-amyloid plaque in subjects diagnosed with Mild Cognitive Impairment. The study is designed to investigate whether scan findings have the ability to distinguish between subjects with MCI who progress to Alzheimer's disease from those who do not.
Comments (1)
  • Joe2922
    , contributor
    Comments (409) | Send Message
    Lock & Load! Lily paid $300M Upfront Cash Plus $500M more in milestones for the inferior Amyvid. NAV4694 in earlier trials proved to be equal to Pib, the gold standard, which can only be used in the clinic due to its super-short half-life. Add in newly approved Lymphoseek, proven superior to anything on the market in Phase 3 trials, and NAV5001 for Parkinsons & Dementia testing, and this stock is a screaming buy. Nice balance sheet with a total $50M line of credit, $35M ready now and only $4.2M used. Virtual co. that has super high gross and net margins as mfg., sales, marketing, distribution are out-sourced, and Cardinal is selling Lymphoseek in the U.S. for next 5 yrs. under contract, with Navidea capturing 53% of end-user price of $300, expected to rise when Sentinel lymph node designation arrives in 2014, the first one ever. Interim results of that trial coming soon, less than 10% false negatives is the primary end point, with Zero% false negatives so far, anecdotally. High short interest appears to be trapped in this stock. Management all have tremendous resumes, Tom Tulip, Cornelia Reisinger, etc, and a great finance partner in Platinum Montaur with huge vested interest in common & preferred stock, aligned with common holder interests.
    27 Mar 2013, 01:11 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: